Literature DB >> 15683749

Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis [correction of antituberclosis] treatment.

M Sharifzadeh1, M Rasoulinejad, F Valipour, M Nouraie, S Vaziri.   

Abstract

For evaluation the extent of antituberculosis drug-induced hepatotoxicity and also to determine the patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity induced by antituberculosis medications, a prospective study was conducted on 112 patients in a tertiary care university teaching hospital for three years. Causality, preventability, predictability and severity of hepatotoxicity were determined based on the available standard algorithms. Of 112 patients, 31 (27.7%) demonstrated hepatotoxicity. Two patients died from complications of liver-related illness. The mean duration of treatment before the onset of hepatotoxicity was 16.7+/-3.2 days. Malnutrition was present in 17 of 112 patients. Most of hepatotoxicity (25/31 or 80.6%) occurred within the first month of treatment. Reintroduction of antituberculosis drugs was possible in 29 of 31 patients. Univariate and multivariate analysis did not show significant relationships between the rate of hepatotoxicity with age, sex, nutrition and nationality. Our results showed that hepatotoxicity induced by antituberculosis drugs is a nonpreventable and unpredictable reaction. The causality of this reaction is classified as category A based on European grading of causality. This study noted that the frequency of hepatotoxicity induced by antituberculosis drugs in Iranian patients is higher than other studied populations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15683749     DOI: 10.1016/j.phrs.2004.10.009

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  17 in total

Review 1.  Hepatotoxicity from antituberculous therapy in the elderly: a systematic review.

Authors:  Jennifer D Hosford; Michael E von Fricken; Michael Lauzardo; Myron Chang; Yunfeng Dai; Jennifer A Lyon; John Shuster; Kevin P Fennelly
Journal:  Tuberculosis (Edinb)       Date:  2014-12-18       Impact factor: 3.131

2.  Hepatoprotective activity of viscosine is mediated by attenuation of hepatic macrophages and iNOS expression in CCl4-intoxicated rats.

Authors:  Hamid Ali; Nurul Kabir; Muhammad Raza Shah; Akhtar Muhammad; Safdar Ali; Shahab Mehmood; Amjad Ali; Abid Ali; Azra Jahan
Journal:  Toxicol Res (Camb)       Date:  2016-09-13       Impact factor: 3.524

3.  Drug-induced Liver Injury.

Authors:  Stefan David; James P Hamilton
Journal:  US Gastroenterol Hepatol Rev       Date:  2010-01-01

Review 4.  Hepatotoxic effects of therapies for tuberculosis.

Authors:  Bahaa E Senousy; Sanaa I Belal; Peter V Draganov
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-08-31       Impact factor: 46.802

5.  Seroprevalence and Associated Factors of Hepatitis B and C Virus Among Pulmonary Tuberculosis Patients Attending Health Facilities in Gondar Town, Northwest Ethiopia.

Authors:  Birhanu Getie; Getnet Ayalew; Anteneh Amsalu; Getachew Ferede; Gizachew Yismaw; Belay Tessema
Journal:  Infect Drug Resist       Date:  2021-09-03       Impact factor: 4.003

Review 6.  Antitubercular therapy in patients with cirrhosis: challenges and options.

Authors:  Naveen Kumar; Chandan Kumar Kedarisetty; Sachin Kumar; Vikas Khillan; Shiv Kumar Sarin
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

7.  Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China.

Authors:  Penghui Shang; Yinyin Xia; Feiying Liu; Xiaomeng Wang; Yanli Yuan; Daiyu Hu; Dehua Tu; Yixin Chen; Peiyuan Deng; Shiming Cheng; Lin Zhou; Yu Ma; Lizhen Zhu; Weiwei Gao; Hongyuan Wang; Dafang Chen; Li Yang; Pingping He; Shanshan Wu; Shaowen Tang; Xiaozhen Lv; Zheng Shu; Yuan Zhang; Zhirong Yang; Yan Chen; Na Li; Feng Sun; Xiaoting Li; Yingjian He; Paul Garner; Siyan Zhan
Journal:  PLoS One       Date:  2011-07-05       Impact factor: 3.240

8.  A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury.

Authors:  Chote Luangchosiri; Ammarin Thakkinstian; Sermsiri Chitphuk; Wasana Stitchantrakul; Supanna Petraksa; Abhasnee Sobhonslidsuk
Journal:  BMC Complement Altern Med       Date:  2015-09-23       Impact factor: 3.659

9.  The Effect of Garcin® in Preventing AntiTB-Induced Hepatitis in Newly Diagnosed Tuberculosis Patients.

Authors:  Payam Tabarsi; Fanak Fahimi; Nader Heidarzadeh; Roodabeh Haghgoo; Mehdi Kazempour; Mohammadreza Masjedi; Ali Akbar Velayati
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

10.  Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control study.

Authors:  Alima Hassen Ali; Tefera Belachew; Alemeshet Yami; Wubeante Yenet Ayen
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.